Citations

Clear

1422 citation(s) found for "White, JB".

cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Louis, David N. , Wesseling, Pieter , Aldape, Kenneth , Capper, David , Cree, Ian A. , Figarella‐Branger, Dominique , Fouladi, Maryam, Haberler, Christine , Hawkins, Cynthia , Komori, Takashi, Ng, Ho‐Keung , Orr, Brent A. , Paulus, Werner, Pietsch, Torsten , Reifenberger, Guido , Rosenblum, Marc, Rous, Brian , Sahm, Felix , Sarkar, Chitra , Solomon, David A. , Tabori, Uri , Bent, Martin J. van den , Deimling, Andreas von , Weller, Michael , White, Valerie A. , Ellison, David W. , Figarella-Branger, Dominique , Pietsch, Torsten , Sarkar, Chitra , Solomon, David A , Weller, Michael , van den Bent, Martin J , Orr, Brent A , Wesseling, Pieter , von Deimling, Andreas , Tabori, Uri , Sahm, Felix , Capper, David , Brat, Daniel J. , Eberhart, Charles G. , Fouladi, Maryam , Fuller, Gregory N. , Giannini, Caterina , Kros, Johan M. , Park, Sung-Hye , Perry, Arie , Rosenblum, Marc

Mayo Clinic

Brain Pathology | April 20, 2020 | Volume: 30 | Issue: 4 | Pages: 844-856

10.1111/bpa.12832 | PMID 32307792 Get It

Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT‐NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles—relating to classification categories, approaches to classification, nomenclature, and grading—that the group hopes will also inform the future classification of CNS neoplasms.
Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.
Porrata, Luis F. , Ristow, Kay M., Geyer, Susan M. , Persky, Daniel O. , White, William L. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana N. , Johnston, Patrick B. , Markovic, Svetomir N. , Colgan, Joseph P. , Witzig, Thomas E. , Habermann, Thomas M.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 931-931

10.1182/blood.v106.11.931.931 Get It

Abstract Absolute lymphocyte count (ALC) recovery post-autologous stem cell transplantation has been documented as an independent predictor for survival in non-Hodgkin lymphoma. The effect of ALC recovery on survival during standard CHOP or R-CHOP chemotherapy for newly diagnosed diffuse large B cell lymphoma (DLBCL) is unknown. To participate in the study, patients required to receive their full treatment with complete blood count determinations at the Mayo Clinic College of Medicine. Of 1633 DLBCL cases seen at the Mayo Clinic College of Medicine between February 1994 through August 2004, 212 consecutive DLBCL patients were eligible for the study. We study ALC recovery as a prognostic factor for progression-free survival (PFS) and overall survival (OS) in DLBCL patients treated with at least 3 cycles of CHOP or R-CHOP. 57% were male and the median age was 66 years (range: 20 – 87); 42% had elevated LDH, only 11% had a PS of 2 or higher; 58% were low stage (I or II); 88% of pts achieved a complete response. ALC was evaluated at the beginning of each treatment cycle, focusing on cycles 1–3 and the 3 month post treatment sample. ALC for each of the cycles were significantly correlated with PFS and OS, with cycle 1 ALC most significantly correlated when accounting for inherent differences based on treatment (Rx) type (i.e. CHOP vs. R-CHOP) as well as high vs. low IPI (PFS: p = 0.0012; OS: p = 0.005). Also, 74 pts achieved an ALC of at least 1,000 during all three cycles, where there was no significant relationship with this incidence and Rx type; this incidence was significantly associated with higher PFS (p = 0.0007) and OS (p = 0.0006), even when accounting for Rx type and high vs. low IPI. In the 179 pts who had 3-month post-Rx ALC data, this was also significantly associated with PFS (p = 0.002) and OS (p = 0.0009), while still accounting for Rx type and IPI status. Achievement of ALC >= 1,000 post-Rx was also significant for PFS (p = 0.0014) and OS (0.003). Also of note, only cycle 1 ALC was significantly different in high vs. low IPI pts (p = 0.008). In summary, these data support the hypothesis that there is a critical role of lymphocyte (immune) recovery during CHOP/R-CHOP chemotherapy in DLBCL.
Absolute Lymphocyte Count Recovery during Standard Chemotherapy Predicts Superior Survival and Is Independent of the Hasenclever Index for Hodgkin’s Disease.
Porata, Luis F., Ristow, Kay M., White, William L. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana N. , Johnston, Patrick B. , Martin, William G., Martenson, James A., Stafford, Scott L., Siddiqui, Mustaqeem , Habermann, Thomas M. , Colgan, Joseph P. , Witzig, Thomas E. , Martin, William G., Markovic, Svetomir N.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 2667-2667

10.1182/blood.v106.11.2667.2667 Get It

Abstract Absolute lymphocyte count (ALC) post-autologous stem cell transplantation is an independent predictor for survival in Hodgkin’s Disease (HD). Lymphopenia at diagnosis is associated with worse prognosis in patients with newly diagnosed HD. The role of ALC recovery during standard chemotherapy for HD is unknown. We analyzed all patients managed for HD at the Mayo Clinic from 1986 to 2003. Of the 141 consecutive patients, two patients were excluded due to missing ALC data. Of the 139 patients, 63 patients were females and 76 males. The median age of patients at diagnosis was 31 years (range 6–75 years). 118 (85%) patients presented with nodular sclerosis HD, 10 (7%) with mixed cellularity, 2 (1%) with lymphocyte predominance, 1(1%) with lymphocyte depletion, 4 (3%) with lymphocyte predominant (nodular variant), and 4 (3%) unclassified. Frontline chemotherapy included ABVD (N = 79), MOPP-ABV (N = 47), COPP-ABV (N = 8), BEACOPP (N = 3), and Stanford V (N =2). The median number of cycles was 6 (range: 2–10). The median follow-up for the cohort was 62 months (range: 4–221 months). The ALC recovery was analyzed during the first 4 cycles as 90% of the patients received at least 4 cycles of therapy. Patients with an ALC ≥ 1.3 x 109/l at any time point within the first four cycles of chemotherapy (N = 93) demonstrated improved overall survival (OS) and progression-free survival (PFS) compared to patients with an ALC < 1.3 x 109/L at all time points within the first four cycles of chemotherapy (N =46) (10 years OS and PFS: 91% vs 51%, p < 0.0001; 85% vs 52%, p < 0.0001, respectively). Both groups were balanced for the Hasenclever Index: albumin < 4g/dl (p = 0.1), hemoglobin < 10.5 g/dl (p = 0.46), male gender (p =0.21), age ≥ 45 years (p = 0.06), stage IV disease (p = 0.68), leukocytosis ≥ 15 x 109/L (p = 0.58), and lymphopenia < 600 cell/ml (p = 0.211). Multivariate analysis demonstrated ALC recovery to be independent predictor of OS and PFS when compared to the Hasenclever index. These data suggest a critical role of lymphocyte (immune) recovery during standard chemotherapy in HD.
Platelet Pathology in GATA-1 Dyserythropoietic Macrothrombocytopenia.
White, James G. , Nichols, William L., Steensma, David P.

Mayo Clinic

Blood | April 19, 2020 | Volume: 108 | Issue: 11 | Pages: 1102-1102

10.1182/blood.v108.11.1102.1102 Get It

Abstract Germline mutations in the X-linked hematopoietic transcription factor, GATA-1, have been associated with dyserythropoietic anemia (DEA), macrothrombocytopenia (MTP), and congenital erythropoietic porphyria. Recently, morphological features suggestive of the Gray Platelet Syndrome (GPS) were described in a pedigree with a germline R216Q GATA-1 mutation (Blood106:6a, 2005). The present study has evaluated platelets (Pl) in the electron microscope from members of a previously described pedigree (Blood98:2681–2688, 2001) with GATA-1 G208S, MTP, and dyserythropoiesis without anemia, for whom detailed platelet morphology studies have not been reported. The presence of a hemizygous GATA-1 mutation was confirmed by conventional fluorescent dye chemistry sequencing of DNA from patient peripheral blood mononuclear cells. Their Pl revealed wide variations in size, shape, internal and external structure. Some normal sized and giant Pl contained usual numbers of alpha granules and dense bodies, while most of the large cells were hypogranular. Some contained no membrane systems or organelles. Others were filled with masses of dense tubular system (DTS) channels, and others contained the tubular inclusions found in the Medich Giant Platelets Disorder (Platelets15:345–353, 2004). Many of the hypogranular cells contained small vacuoles that may have been enclosing membranes of alpha granules. Except for the tubular inclusions, all of these structural variations are observed in GPS Pl (Am. J. Pathol.95:445–462, 1979). However, additional striking abnormalities were seen in GATA-1 Pl that are not characteristic of GPS Pl. Many GATA-1 Pl contained unusual, closely associated dense double membranes differing from normal elements of rough endoplasmic reticulum, smooth endoplasmic reticulum, DTS or surface connected open canalicular system (OCS), but resembling channels of the OCS after exposure to EDTA. They were observed previously only in megakaryocytes (Mk) from one family with GATA-1 DEA-MTP (Nat. Genet, 24:266–270, 2000). The dense double membranes were often found in parallel association and, in some examples, isolating areas of cytoplasm. However, the isolated areas were not undergoing autophagic degradation as such areas enclosed by elements of the DTS do in White Platelet Syndrome Pl (Platelets 15:173,2004). Instead, they proved to be another unique feature of GATA-1 platelets, the presence of Pl within Pl. The sequestered cells were usually mature in appearance and often discoid in form with circumferential coils of microtubules. In some GATA-1 Pl there were two Pl within the same cell, and on rare occasions, a Pl within a Pl within a Pl. Pl within Pl have never been observed previously in any human platelet disorder. Another unique feature, related to Pl within Pl, was the frequent Pl to Pl surface attachment of non-activated cells forming large macrothrombocytes with no similarity to aggregates of stimulated normal platelets. Conclusion: The substructural abnormalities of Pl from patients with germline GATA-1 mutations share some overlap with those seen in GPS Pl, but are distinct and unique. The MTP, Pl within Pl and surface Pl to Pl attachments suggest a major defect in the formation and separation of GATA-1 Pl from pro-Pl of the parent Mk, resulting in the MTP characteristic of the disorder.
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial
White, Darrell , Marcellus, Deborah, Belch, Andrew R. , Stewart, A. Keith, Chen, Christine , Kovacs, Michael J., MacDonald, David , Reece, Donna , Harnett, Erica, Chapman, Judy‐Anne W., Meyer, Ralph M., Bahlis, Nizar Jacques

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 2767-2767

10.1182/blood.v112.11.2767.2767 Get It

Abstract Introduction: The NCIC CTG previously reported the results of a dose-finding trial testing the combination of Melphalan (M) and Lenalidomide (L) in previously untreated patients with multiple myeloma who were ineligible for stem cell transplantation because of older age and/or comorbidity (White, Blood2007; 110: 63a). Using a 28-day schedule, M (dose indicated as mg/m2/day given on days 1–4) and L (dose indicated in mg/day given on days 1–21) was associated with excess toxicity with the regimens M9L10, M4L15 and M6L10. We concluded that phase II testing of M5L10 was warranted and now report the results of this testing. Methods: Previously untreated symptomatic and consenting patients with tissue-confirmed plasmacytosis and a measurable M-protein were eligible provided that they had acceptable hematologic and biochemical laboratory parameters and no precluding comorbidities. Planned treatment consisted of M 5 mg/m2 days 1–4 and L 10 mg days 1–21, given every 28 days for 12 cycles. As our intent was to determine dose levels that could be given independently of G-CSF, primary prophylaxis with G-CSF was not included but use of G-CSF for established neutropenia was permitted. A hematologic dose limiting toxicity (H-DLT) was defined as the need for 2 dose attenuations of L or 1 dose attenuation of M occurring within the first 3 treatment cycles. Responses to treatment were classified using 1998 EBMT criteria and assessed after 2 and 6 cycles of therapy. Results: The intended sample size was 41 patients; 35 patients (1 ineligible) were enrolled before the study was closed due to observing a frequency of DLTs that surpassed predefined boundaries. Of the 34 eligible patients, median age was 73.4 yrs and ISS was stage I = 13, stage II = 11 and stage III = 10. Prior to study closure, 27 patients were evaluable for DLT; 7 (26%) did not experience a DLT. Among the remaining 20 (74%) patients, non-hematologic (N=2) and hematologic (N=18) DLTs requiring dose attenuations were seen within the first 3 treatment cycles; the H-DLTs included severe or prolonged neutropenia (N=11), thrombocytopenia (N=2) or both (N=5). One fatal serious adverse event was observed, this was due to a stroke. The other non-hematologic DLT was a cranial nerve III palsy which subsequently resolved. Responses after 2 cycles were evaluable in 21 patients and included partial response (PR) = 11, minimal response = 6, no change = 2 and progressive disease (PD) = 2. For those patients without PD after 2 cycles, responses after 6 cycles were evaluable in 8 and included PR = 6, stable response = 1 and PD = 1. Conclusion: Although M + L is an active combination for previously untreated myeloma patients, the regimen is associated with considerable myelosuppression. Without the routine use of GCSF, the doses used in the MY.11 study were not tolerable. Inability to use planned doses may have compromised the efficacy of the combination.
Tissue Specific Expression of Alternatively Spliced Forms of Tissue Factor Pathway Inhibitor (TFPI) in Mice
Maroney, Susan A. , Ferrel, Josephine P., Pan, Shuchong, White, Thomas A. , Simari, Robert D., Mast, Alan E. , McVey, John H.

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 1026-1026

10.1182/blood.v112.11.1026.1026 Get It

Abstract TFPI is an endothelium associated anticoagulant protein that directly inhibits tissue factor (TF) pro-coagulant activity and prevents disease produced by intravascular thrombosis. TFPI is produced in three alternatively spliced isoforms in mice, α, β and γ, that differ in domain structure and mechanism for association with endothelium. TFPIα has three Kunitz-type serine protease inhibitory domains and a basic C-terminal region. It produces anticoagulant activity by direct inhibition of factor Xa (fXa) via the second Kunitz domain (K2) and, in a fXa dependent manner, inhibition of TF-fVIIa via the first Kunitz domain (K1). The third Kunitz domain (K3) and C-terminal region do not directly inhibit proteolysis. However, alignment of sequences from various vertebrate species demonstrates that K3 has maintained a high degree of sequence conservation for over 430 million years suggesting that K3 maintains a physiological function. TFPIα indirectly associates with endothelium by binding to a glycosylphosphatidyl inositol (GPI) anchored protein and binds non-specifically to glycosaminoglycans. TFPIβ has K1 and K2 but lacks K3 and has a distinct C-terminal region that encodes a GPI-anchor attachment sequence. TFPIγ has K1 and K2 but lacks K3 and has a distinct C-terminal region that results in production of a secreted protein. It is not known if these structurally diverse forms of TFPI with different mechanisms for cell surface association have variable efficacy in their ability to inhibit TF activity in vivo. We characterized TFPI isoform expression in mouse tissues in order to define specific physiological functions for alternative splicing of TFPI and how it may hinder diseases mediated by intravascular TF activity. Message for TFPIα is ~16-fold more abundant than message for TFPIβ or TFPIγ in mouse tissues. In situ hybridization studies of mouse heart and lung found that the isoforms are expressed in the same pattern, primarily in endothelial cells. No cell or vascular bed exclusively producing a single isoform was identified. Western blot analyses revealed the somewhat surprising finding that TFPIβ is the predominant isoform produced by adult mouse tissues. Thus, protein synthesis of TFPI isoforms in mice is regulated at least in part at the level of protein translation. Mouse plasma TFPI levels increase only 10–20% following heparin infusion. These data contrast with the 2- to 4-fold increase in plasma TFPI observed following heparin infusion in humans. The presence of only small amounts of heparin releasable TFPI in mouse plasma is consistent with TFPIβ as the major isoform because TFPIβ is directly GPI-anchored to endothelium and lacks the highly basic C-terminal region that allows TFPIα to associate non-specifically with endothelium glycosaminoglycans. To our knowledge, these are the first data demonstrating TFPIβ production in vivo. In contrast to the adult tissues, western blot analysis of mouse placenta revealed that it produces primarily TFPIα. This finding led us to examine mouse fetal tissue to determine if there is developmental regulation of the production of different TFPI isoforms. These studies demonstrated that TFPIα and TFPIβ are produced in approximately equal amounts in E14.5 embryos. The relative proportion of TFPIα in mouse tissues then decreases during development and very little is produced at 12 weeks of age. The evolutionary conservation of TFPIα and its production in mouse placenta and embryonic tissues suggests that unique features of TFPIα, such as K3, the basic C-terminal region and/or its binding to the endothelial surface through a GPI-anchored co-receptor, perform specific functions in the regulation of intravascular TF activity during vasculogenesis/angiogenesis that are not performed by TFPIβ or TFPIγ.
Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.
Porrata, Luis F. , Ristow, Kay M., Haberman, Thomas M, Inwards, David J. , Ansell, Stephen M. , Johnston, Patrick B. , Micallef, Ivana N. , White, William L. , Witzig, Thomas E. , Colgan, Joseph P. , Markovic, Svetomir N.

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 1763-1763

10.1182/blood.v112.11.1763.1763 Get It

Abstract The International Prognostic Index at the time of relapse (IPI-R) has been reported to predict clinical outcome in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplantation (ASCT) [Jabbour et al, Leukemia & Lymphoma2005;46(6):861–867; Lerner et al, Biology of Blood and Marrow Transplant2006;13:486–492; and Costa et al, Bone Marrow Transplant2008;41:715–720]. The absolute lymphocyte count (ALC) has been reported as a prognostic factor for survival at diagnosis, during standard chemotherapy and at day 15 post-ASCT for multiple hematological malignancies; however, no reports have addressed whether ALC at the time of relapse (ALC-R) predicts survival. Thus, we assessed the prognostic significance of ALC-R in patients with relapsed DLBCL. To be included in the study, patients were required to have been diagnosed with relapsed DLBCL, have ALC values available from the time of relapse, and to be followed at Mayo Clinic, Rochester. From Feb 2,1987 until March 6, 2006, 121 DLBCL patients qualified for the study. The overall survival (OS) was measured from the time of relapse to the date of death or last follow-up and progression-free survival (PFS) was defined as the time from relapse to the time of progression, relapse, death, or last follow-up. The median age at relapse was 68 years (range:25–88 years) and the median ALC-R was 1.21 x 109/L (range: 0.33–5.99 x 109/L). The value of ALC-R ≥ 1.0 x 109/L was used for the analysis based on previous publications. The groups (ALC-R ≥ 1 or < 1 x 109/L) were balanced for the IPI-R (p=0.1), as well as for undergoing ASCT (p=0.4). Superior OS was observed in patients with an ALC-R ≥ 1.0 x 109/L (N = 76) [median OS: 27.5 months, 3 years OS rates of 42%] compared with patient with an ALC-R < 1.0 x 109/L (N =45) [median OS: 9.4 months, 3 years OS rates of 13%] (p <0.0001). Superior PFS was also observed in patients with an ALC-R ≥ 1.0 x 109/L (N = 76) [median PFS: 14.8 months, 3 years PFS rates of 30%] compared with patient with an ALC-R < 1.0 x 109/L (N =45) [median PFS: 6.2 months, 3 years PFS rates of 11%] (p <0.001). ALC-R was an independent prognostic factor for OS [RR = 0.551, p < 0.009] and PFS [RR = 0.674, p < 0.02] in the multivariate analysis when compared with the IPI-R and whether patients underwent ASCT or not. Our study supports the hypothesis that ALC at relapse predicts clinical outcome in DLBCL and suggests that patient host immunity is an important variable predicting survival in relapsed DLBCL.
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.
White, Darrell , Kovacs, Michael J., Belch, Andrew R. , Stewart, Keith, Chen, Christine , Rubin, S., MacDonald, David , Harnett, Erica, Chapman, Judy‐Anne W., Shepherd, Lois E. , Meyer, Ralph M.

Mayo Clinic

Blood | April 18, 2020 | Volume: 110 | Issue: 11 | Pages: 189-189

10.1182/blood.v110.11.189.189 Get It

Abstract Introduction. The NCIC CTG is conducting phase II testing to establish the tolerability and estimate the efficacy of combining lenalidomide (L) + melphalan (M) over multiple cycles for previously untreated patients with multiple myeloma who are ineligible for stem cell transplantation. We report the data from the preliminary safety phase of this trial. Methods. The MY.11 trial was initially designed as a randomized phase II test of M 9 mg/m2 given on days 1–4 (M9) plus either L 10 mg (L10) or 20 mg given on days 1–21 of a 28 day cycle. Primary prophylaxis with G-CSF was not included, but use of G-CSF for established neutropenia was permitted; our intent was to determine dose levels that could be given independently of G-CSF. A dose attenuation schedule was developed for neutropenia and/or thrombocytopenia that was severe and occurred during the administration of L or was persistent and caused a delay in the next treatment cycle. A hematologic dose limiting toxicity (H-DLT) was defined as the need for 2 dose attenuations of L or 1 dose attenuation of M. Prior to the randomized phase of the trial, a safety run-in phase testing M9+L10 in 6 patients was planned; closure of this arm was to occur if, during the first 3 treatment cycles, there were ≥ 3 H-DLTs or any non-hematologic serious adverse event (SAE) judged to be treatment related. Four of the planned 6 patients were entered; during their first 3 treatment cycles, each experienced a H-DLT and one died from sepsis. The study was therefore amended with the intent to conduct a randomized phase II test of M 4 mg/m2 days 1–4 plus L 15 mg days 1–21 (M4L15) and M 6 mg/m2 days 1–4 plus L 10 mg days 1–21 (M6L10). Prior to the randomized phase of testing, each regimen was tested in non-randomized safety run-ins that included 6 patients per arm. The same parameters as above for study arm closure were applied. If the M6L10 arm was closed, the trial would proceed to test M 5 mg/m2 days 1–4 and L 10 mg days 1–21 (M5L10). Results. Six patients were enrolled to M4L15: during their first 3 treatment cycles, 4 patients experienced H-DLTs related to severe or persistent grade 3–4 neutropenia and one other patient experienced an SAE related to hallucinations and multiple constitutional complaints. This arm was therefore closed to accrual. Six patients were enrolled to M6L10: during their first 3 treatment cycles, 3 patients experienced H-DLTs related to severe or persistent grade 3–4 neutropenia. One of these patients was hospitalized with pulmonary edema and another with febrile neutropenia. This arm was therefore closed and the MY.11 trial amended to proceed as a single-arm phase II testing M5L10. Conclusion. Although M + L holds promise as an effective combination for previously untreated myeloma patients, the regimen is associated with considerable myelosuppression. The efficacy of the combination when given at tolerable doses remains to be established.
90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.
Inwards, David J. , Spies, Stewart, Wiseman, Gregory A., Erwin, William D. , Rademaker, Alfred , Williams, Stephanie , Tallman, Martin S. , Micallef, Ivana N. , Mehta, Jayesh, Zimmer, Michael, Molina, Arturo , Winter, Jane N. , Patton, David R. , Singhal, Seema , Zimmer, Michael, White, Christine, Gordon, Leo I.

Mayo Clinic

Blood | April 18, 2020 | Volume: 104 | Issue: 11 | Pages: 1162-1162

10.1182/blood.v104.11.1162.1162 Get It

Abstract Twenty-eight patients with relapsed or refractory CD20+ NHL have been enrolled in an ongoing phase I trial of dose-escalated 90YZ followed by high-dose BEAM and autotransplant in which the 90YZ dose is patient-specific based on dosimetry. 90YZ doses are calculated to deliver cohort-defined radiation doses (100, 300, 500, ... cGy) to critical organs (liver, lung or kidney), with 3–6 patients per group. On D -22, rituximab (R) 250 mg/m2 is infused followed by the imaging dose of 111In Zevalin® (5 mCi). Imaging is performed immediately post-injection and at 4, 24, 72, and 144 hours; dosimetry is performed on D -15. On D -14, R 250 mg/m2 is administered followed immediately by 90YZ at the dose calculated to deliver the cohort-prescribed absorbed radiation dose to the critical organ. On D -6 through -1, patients receive high-dose BEAM. On D0, a minimum of 2.0 X 106 CD34+ cells/kg is infused and G-CSF 5 μg/kg SQ daily begun. The median age was 54 (range: 25–72) years. NHL histologic subtypes were as follows: mantle cell 5, diffuse aggressive 13, low grade 5, and transformed 5. Most had received 3 or more treatment regimens, including R. The toxicity profile was similar to that associated with high-dose BEAM and included a decrease in DLCO for most patients with one patient at the 500 cGy dose level experiencing a transient decline to below 50% of the predicted value corrected for hemoglobin. The most common grade III/IV toxicities were infection, fever, stomatitis, nausea, vomiting, diarrhea, hemorrhage, and edema. One patient experienced transient veno-occlusive disease at the 700 cGy dose level. Engraftment occurred at a median of 10 days (range:8–18) to granulocytes ≥ 500/μL, and 21 days (range:13–40days) to platelets ≥20,000/μL . With a median follow-up of one year, the 3 year overall and progression-free survivals are 60% and 50%, respectively. Figure Figure 90-Y Zevalin Dosing by Cohort (median; range) Cohort (cGy) Total Dose (mCi) mCi/kg 100 (n=3) 5 (2–14) .06(.05–.12) 300 (n=7) 22(14–57) .25(.18–.63) 500 (n=6) 31(16–48) .40(.14–.63) 700 (n=6) 37(26–55) .38(.27–.73) 900 (n=3) 28(27–37) .32(.27–.44) 1100 (n=3) 48(29–65) .57(.50–.75) The liver was the critical organ in nearly all cases. Patient-specific doses calculated to deliver a cohort-prescribed absorbed radiation dose to the critical organ were highly variable suggesting that dosing based on weight and not dosimetry is likely to result in a wide range of absorbed dose to critical organs. In the context of this study, 90YZ has been administered to eight patients at doses of .5 mCi/kg or greater. We conclude that with careful dosimetry, 90YZ doses higher than the conventional .4 mCi/kg may be safely combined with BEAM and autotransplant. Accrual continues at the 1300 cGy dose level.
Effect of Natural Menopause and Hormone Therapy on Markers of Cellular Senescence
Faubion, Laura L. , White, Thomas A. , Peterson, Brett J., Miller, Virginia M. , Singh, Atul Kumar , Mielke, Michelle M.

Mayo Clinic

The FASEB Journal | April 16, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.02879 Get It

Background Accumulation of senescent cells and the release of proteins from those cells contribute to aging‐related disorders. Estrogen may reduce physiological changes associated with aging through inhibition of cell senescence. This study aimed to determine the effects of menopausal hormone treatments on circulating levels of cell senescence markers. Methods GDF 15, TNF R1, FAS, and MIP1α were measured in serum using bead‐based assays and compared among women who were within 3 years of natural menopause (mean age 52 years) participating in the Kronos Early Estrogen Prevention Study (KEEPS). Women were randomized to either placebo (n=38), oral conjugated equine estrogen (oCEE, n=37), or transdermal 17β‐estradiol (tE2, n=34). Serum levels of the senescent markers for each treatment group were compared to placebo 36 months after randomization using the Wilcoxon rank‐sum test. Results Serum levels of GDF 15, TNF R1, and FAS but not MIP1α were lower in both the oCEE and tE2 groups compared to placebo. However, the difference in levels between treatment and placebo were greater for oCEE [−108 pg/mL (p=0.008), −234 pg/mL (p=0.0006), and −1374 pg/mL (p<.0001), respectively] than for tE2 [−76 pg/mL (p=0.072), −105 pg/mL (p=0.076), and −695 pg/mL (p=0.036), respectively]. Conclusions In recently menopausal women, oCEE and tE2 reduced circulating levels of some markers of cell senescence. Differences in the magnitude of effect may reflect the differences in circulating levels of 17β estradiol, estrone, and sulfonated estrogens between the two active treatments. Support or Funding Information The research is supported by the Kronos Early Estrogen Prevention Study, NIA U54‐AG44170, and the Mayo Fnd.